China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHA:600062)

SHA:600062 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	10,854	11,119	11,177	9,522	9,034	8,391
Other Revenue	92.76	92.76	133.12	102.99	77.88	112.69
Revenue	10,947	11,212	11,310	9,625	9,112	8,504
Revenue Growth (YoY)	-4.06%	-0.87%	17.50%	5.64%	7.14%	-9.35%
Cost of Revenue	4,652	4,832	4,904	4,307	4,048	3,157
Gross Profit	6,295	6,380	6,406	5,318	5,064	5,347
Selling, General & Admin	4,053	4,127	3,937	3,478	3,502	3,764
Research & Development	453.68	555.19	627.85	482.48	409.59	291.02
Other Operating Expenses	68.37	75.98	106.24	119.35	115.75	114.41
Operating Expenses	4,585	4,739	4,681	4,081	4,029	4,173
Operating Income	1,710	1,641	1,725	1,237	1,034	1,173
Interest Expense	-30.34	-15.36	-15.4	-10.62	-11.62	-3.66
Interest & Investment Income	185.15	198.56	190.56	89.68	81.55	51.33
Earnings From Equity Investments	-48.8	-	-	16.23	-	-
Currency Exchange Gain (Loss)	9.19	9.19	6.6	18.06	-4.97	-0.48
Other Non Operating Income (Expenses)	-1	-2.32	61.3	6.36	0.26	-10.33
EBT Excluding Unusual Items	1,824	1,831	1,968	1,357	1,099	1,210
Impairment of Goodwill	-29.41	-29.41	-28.9	-	-56.68	-43.42
Gain (Loss) on Sale of Investments	1.65	-1.64	13.7	5.99	35.36	29.05
Gain (Loss) on Sale of Assets	44	46.84	0.18	-2.27	1.03	-22.52
Asset Writedown	-48.86	-59.17	-57.52	-8.43	-0.54	-0.12
Other Unusual Items	78.87	78.87	40.85	82.76	42.65	41.92
Pretax Income	1,870	1,867	1,937	1,435	1,121	1,215
Income Tax Expense	243	215.94	272.71	201.27	149.06	201.52
Earnings From Continuing Operations	1,627	1,651	1,664	1,234	972.13	1,013
Minority Interest in Earnings	-47	-23.02	6.29	-53.59	-36.45	-8.33
Net Income	1,580	1,628	1,670	1,180	935.69	1,005
Net Income to Common	1,580	1,628	1,670	1,180	935.69	1,005
Net Income Growth	-6.23%	-2.55%	41.55%	26.12%	-6.91%	-4.74%
Shares Outstanding (Basic)	1,031	1,028	1,024	1,036	1,043	1,043
Shares Outstanding (Diluted)	1,032	1,028	1,024	1,036	1,043	1,043
Shares Change (YoY)	0.57%	0.33%	-1.07%	-0.74%	-	0.00%
EPS (Basic)	1.53	1.58	1.63	1.14	0.90	0.96
EPS (Diluted)	1.53	1.58	1.63	1.14	0.90	0.96
EPS Growth	-6.77%	-2.87%	43.09%	27.06%	-6.91%	-4.74%
Free Cash Flow	959.96	1,188	1,245	889.57	849.25	1,012
Free Cash Flow Per Share	0.93	1.16	1.22	0.86	0.81	0.97
Dividend Per Share	0.471	0.471	0.257	0.578	0.480	0.290
Dividend Growth	31.93%	83.27%	-55.54%	20.42%	65.52%	-4.61%
Gross Margin	57.50%	56.91%	56.64%	55.25%	55.57%	62.87%
Operating Margin	15.62%	14.64%	15.26%	12.85%	11.35%	13.80%
Profit Margin	14.44%	14.52%	14.77%	12.26%	10.27%	11.82%
Free Cash Flow Margin	8.77%	10.59%	11.01%	9.24%	9.32%	11.90%
EBITDA	2,466	2,358	2,390	1,778	1,482	1,548
EBITDA Margin	22.53%	21.03%	21.13%	18.47%	16.26%	18.20%
D&A For EBITDA	756.48	717.07	664.52	540.36	447.4	374.36
EBIT	1,710	1,641	1,725	1,237	1,034	1,173
EBIT Margin	15.62%	14.64%	15.26%	12.85%	11.35%	13.80%
Effective Tax Rate	12.99%	11.57%	14.08%	14.03%	13.30%	16.59%
Revenue as Reported	10,947	11,212	11,310	9,625	9,112	8,504
Advertising Expenses	-	85.96	35.82	-	-	45.64

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.